Synergy between dendritic cell-based vaccine and anti-CD137 monoclonal antibody in the treatment of mouse renal cell carcinoma
KMJ-Kuwait Medical Journal. 2012; 44 (4): 308-315
en Inglés
| IMEMR
| ID: emr-171928
ABSTRACT
Therapeutic efficacy of dendritic cell-based vaccine for renal cell carcinoma remains limited. In this study, we investigated whether anti-CD137 monoclonal antibody is capable of potentiating anti-tumor effect of dendritic cellbased vaccine. Experimental study. Research laboratory. Balb/c mice [8-10 weeks old]. A renal cell carcinoma model was established by subcutaneous injection of Renca tumor cells into Balb/c mice on day 0. After three days, tumor-bearing mice were treated with Renca tumor lysate-pulsed dendritic cells [i.e., dendritic cell-based vaccine], anti-CD137 monoclonal antibody, or combination of Renca tumor lysate-pulsed dendritic cells with anti-CD137 monoclonal antibody. Mice were killed on day 20 after tumor cell inoculation, and spleens were harvested for analysis of anti-tumor immune responses. The anti-tumor immune responses were analyzed by measuring proliferation and activity of T cells, which have the ability to kill tumor cells. The anti-tumor effect was assessed by measuring tumor size. The combination therapy with Renca tumor lysatepulsed dendritic cells and anti-CD137 antibody significantly increased T-cell proliferation and activity, and significantly inhibited tumor growth, compared with a single treatment with Renca tumor lysate-pulsed dendritic cells or anti-CD137 antibody. These results suggest that combination therapy can enhance anti-tumor effect by increasing T-cell proliferation and activity
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Células Dendríticas
/
Vacunas
/
Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral
/
Inmunoterapia
/
Neoplasias Renales
/
Ratones Endogámicos BALB C
/
Anticuerpos Monoclonales
Límite:
Animales
Idioma:
Inglés
Revista:
Kuwait Med. J.
Año:
2012
Similares
MEDLINE
...
LILACS
LIS